Headquartered in Dallas, TX Fiscal year ends December NASDAQ: CGON cgoncology.com
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing cretostimogene grenadenorepvec, an investigational intravesically delivered oncolytic immunotherapy for patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company's clinical development program includes more than 600 patients and encompasses two Phase 3 clinical trials: BOND-003 for high-risk BCG-unresponsive NMIBC and PIVOT-006 for intermediate-risk NMIBC, as well as a multi-cohort Phase 2 trial (CORE-008) evaluating safety and efficacy across various NMIBC patient populations. The company also operates an Expanded Access Program for cretostimogene in North America. CG Oncology's pipeline is centered on providing a bladder-sparing therapeutic alternative for bladder cancer patients, with the goal of becoming a backbone therapy in the treatment of NMIBC. Updated
The highlight of recent insider buying is an enormous purchase of Tesla shares by CEO Elon Musk. But it wasn't the only notable buy in the past week or so.
As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at these biotech companies.
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing cretostimogene grenadenorepvec, an investigational intravesically delivered oncolytic immunotherapy for patients with Non-Muscle Invasive Bladder Cancer (NMIBC).
The Wall Street consensus 12-month price target for CGON is $91.08.
